Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment hurdles, growth plans set for 2025.
Latest Ratings for EXAS
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | Wells Fargo | Maintains | Equal-Weight | |
| Feb 2022 | Citigroup | Maintains | Neutral | |
| Feb 2022 | Raymond James | Maintains | Outperform |
